J. Castellsague

First name
J.
Last name
Castellsague
Gutthann, P., Rodriguez, L. A. G., Castellsague, J., & Oliart, D. (1997). Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Bmj.
Rodriguez, L. A. G., Duque, A., Castellsague, J., Perez-Gutthann, S., & Stricker, B. H. (1999). A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol.
Castellsague, J., Gutthann, P., & Rodriguez, L. A. G. (1998). Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf.
Castellsague, J., Garcia-Rodriguez, L. A., Duque, A., & Perez, S. (2002). Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatol.
Huerta, C., Castellsague, J., Varas-Lorenzo, C., & Rodriguez, L. A. G. (2005). Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. http://doi.org/10.1053/j.ajkd.2004.12.005
Huerta, C., Varas-Lorenzo, C., Castellsague, J., & Rodriguez, L. A. G. (2006). Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. http://doi.org/10.1136/hrt.2005.082388
Kuiper, J. G., van Herk-Sukel, M. P. P., Castellsague, J., Pottegard, A., Berglind, I. A., Dedman, D., et al. (2018). Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. Drugs Real World Outcomes. http://doi.org/10.1007/s40801-018-0133-1
Rebordosa, C., Plana, E., Aguado, J., Thomas, S., Garcia-Gil, E., Perez-Gutthann, S., & Castellsague, J. (2018). GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4448
Castellsague, J., Kuiper, J. G., Pottegard, A., Berglind, A., Dedman, D., Gutierrez, L., et al. (2018). A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. http://doi.org/10.2147/clep.s146442
Rebordosa, C., Aguado, J., Plana, E., Thomas, S., Frances, A., Lei, A., et al. (2019). Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. http://doi.org/10.1016/j.rmed.2019.04.018